Journal article · 2019 · Open access
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria
New England Journal of Medicine, 380(3), 229–241 · Published 16 January 2019 · DOI 10.1056/nejmoa1802537
In brief
“Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria” is a 2019 journal article by Alejandro Llanos‐Cuentas and 30 co-authors, published in New England Journal of Medicine. OpenAlex counts 265 citations as of 20 November 2026, which puts it in the top 1% of works published in 2019 by citations. It is open access: the full text is free to read at Oxford University Research Archive (ORA) (University of Oxford).
- Citations
- 265
- Most cited in
- 2021 (54)
- Field-weighted impact
- 28.50
- References
- 25
- Authors
- 31
Abstract
BACKGROUND: Tafenoquine, a single-dose therapy for Plasmodium vivax malaria, has been associated with relapse prevention through the clearance of P. vivax parasitemia and hypnozoites, termed "radical cure." METHODS: We performed a phase 3, prospective, double-blind, double-dummy, randomized, controlled trial to compare tafenoquine with primaquine in terms of safety and efficacy. The trial was conducted at seven hospitals or clinics in Peru, Brazil, Colombia, Vietnam, and Thailand and involved patients with normal glucose-6-phosphate dehydrogenase (G6PD) enzyme activity and female patients with moderate G6PD enzyme deficiency; all patients had confirmed P. vivax parasitemia. The patients were randomly assigned, in a 2:1 ratio, to receive a single 300-mg dose of tafenoquine or 15 mg of primaquine once daily for 14 days (administered under supervision); all patients received a 3-day course of chloroquine and were followed for 180 days. The primary safety outcome was a protocol-defined decrease in the hemoglobin level (>3.0 g per deciliter or ≥30% from baseline or to a level of <6.0 g per deciliter). Freedom from recurrence of P. vivax parasitemia at 6 months was the primary efficacy outcome in a planned patient-level meta-analysis of the current trial and another phase 3 trial of tafenoquine and primaquine (per-protocol populations), and an odds ratio for recurrence of 1.45 (tafenoquine vs. primaquine) was used as a noninferiority margin. RESULTS: A protocol-defined decrease in the hemoglobin level occurred in 4 of 166 patients (2.4%; 95% confidence interval [CI], 0.9 to 6.0) in the tafenoquine group and in 1 of 85 patients (1.2%; 95% CI, 0.2 to 6.4) in the primaquine group, for a between-group difference of 1.2 percentage points (95% CI, -4.2 to 5.0). In the patient-level meta-analysis, the percentage of patients who were free from recurrence at 6 months was 67.0% (95% CI, 61.0 to 72.3) among the 426 patients in the tafenoquine group and 72.8% (95% CI, 65.6 to 78.8) among the 214 patients in the primaquine group. The efficacy of tafenoquine was not shown to be noninferior to that of primaquine (odds ratio for recurrence, 1.81; 95% CI, 0.82 to 3.96). CONCLUSIONS: Among patients with normal G6PD enzyme activity, the decline in hemoglobin level with tafenoquine did not differ significantly from that with primaquine. Tafenoquine showed efficacy for the radical cure of P. vivax malaria, although tafenoquine was not shown to be noninferior to primaquine. (Funded by GlaxoSmithKline and Medicines for Malaria Venture; GATHER ClinicalTrials.gov number, NCT02216123 .).
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Llanos‐Cuentas, A., Lacerda, M., Hien, T. T., Vélez, I. D., Namaik-larp, C., Chu, C. S., Villegas, M. F., Val, F., Monteiro, W. M., Brito, M. A. M., Costa, M. R. F., Chuquiyauri, R., Casapía, M., Nguyen, C. H., Aruachán, S., Papwijitsil, R., Nosten, F. H., Bancone, G., Angus, B., . . . Green, J. A. (2019). Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. New England Journal of Medicine, 380(3), 229–241. https://doi.org/10.1056/nejmoa1802537
MLA 9
Llanos‐Cuentas, Alejandro, et al. “Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.” New England Journal of Medicine, vol. 380, no. 3, 2019, pp. 229–241. https://doi.org/10.1056/nejmoa1802537.
Chicago
Llanos‐Cuentas, Alejandro, Marcus Lacerda, Tran Tinh Hien, Iván Darío Vélez, Chayadol Namaik-larp, Cindy S. Chu, María Fernanda Villegas, et al. 2019. “Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.” New England Journal of Medicine 380 (3): 229–241. https://doi.org/10.1056/nejmoa1802537.
Harvard
Llanos‐Cuentas, A. et al. (2019) ‘Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria’, New England Journal of Medicine, 380(3), pp. 229–241. doi:10.1056/nejmoa1802537.
IEEE
A. Llanos‐Cuentas et al., “Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria,” New England Journal of Medicine, vol. 380, no. 3, pp. 229–241, 2019, doi: 10.1056/nejmoa1802537.
BibTeX
@article{llanoscuentas2019tafenoquine,
title = {{Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria}},
author = {Llanos‐Cuentas, Alejandro and Lacerda, Marcus and Hien, Tran Tinh and Vélez, Iván Darío and Namaik-larp, Chayadol and Chu, Cindy S. and Villegas, María Fernanda and Val, Fernando and Monteiro, Wuelton Marcelo and Brito, Marcelo Augusto Mota and Costa, Mônica Regina Farias and Chuquiyauri, Raúl and Casapía, Martín and Nguyen, Chau H. and Aruachán, Sandra and Papwijitsil, Ratchadaporn and Nosten, François Henry and Bancone, Germana and Angus, Brian and Duparc, Stephan and Craig, Graham and Rousell, Victoria M. and Jones, Siôn W. and Hardaker, Elizabeth and Clover, Donna D. and Kendall, Lindsay and Mohamed, Khadeeja and Koh, Gavin C. K. W. and Wilches, Viviana and Breton, John and others},
journal = {New England Journal of Medicine},
year = {2019},
volume = {380},
number = {3},
pages = {229--241},
doi = {10.1056/nejmoa1802537},
url = {https://doi.org/10.1056/nejmoa1802537}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2019 | 19 | |
| 2020 | 38 | |
| 2021 | 54 | |
| 2022 | 34 | |
| 2023 | 27 | |
| 2024 | 40 | |
| 2025 | 30 | |
| 2026 | 23 |
Its field-weighted citation impact is 28.50: it has been cited 28.50 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- tafenoquine
- primaquine
- vivax malaria
- relapse prevention
- radical cure
- hypnozoites
- glucose-6-phosphate dehydrogenase deficiency
- hemoglobin decrease
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Llanos‐Cuentas, A., Lacerda, M., Hien, T. T., Vélez, I. D., Namaik-larp, C., Chu, C. S., Villegas, M. F., Val, F., Monteiro, W. M., Brito, M. A. M., Costa, M. R. F., Chuquiyauri, R., Casapía, M., Nguyen, C. H., Aruachán, S., Papwijitsil, R., Nosten, F. H., Bancone, G., Angus, B., . . . Green, J. A. (2019). Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. New England Journal of Medicine, 380(3), 229–241. https://doi.org/10.1056/nejmoa1802537
How many times has this paper been cited?
265 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Oxford University Research Archive (ORA) (University of Oxford): sign in and open the PDF from this page.
Who wrote this paper?
Alejandro Llanos‐Cuentas, Marcus Lacerda, Tran Tinh Hien, Iván Darío Vélez, Chayadol Namaik-larp, Cindy S. Chu, María Fernanda Villegas, Fernando Val, Wuelton Marcelo Monteiro, Marcelo Augusto Mota Brito, Mônica Regina Farias Costa, Raúl Chuquiyauri and 19 more.
What is the DOI of this paper?
10.1056/nejmoa1802537, permanently at https://doi.org/10.1056/nejmoa1802537. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.